Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06953726 · ClinicalTrials.gov registry record · Phase 4
Comparing the Safety and Efficacy of Apixaban and Rivaroxaban
A Phase 4 study, sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 10,000
- Enrollment target
NCT06953726: Recruiting Phase 4 study, sponsored by VA Office of Research and Development.
NCT06953726 is a Phase 4 study that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 10,000 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06953726, a Phase 4 study, is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 10,000 participants
- Enrollment target
Study Summary
* The trial will compare two anticoagulants ("blood thinners") that are currently used in the VA and are considered standard care to prevent strokes in patients with atrial fibrillation. The two most commonly-used anticoagulants will be compared: apixaban (Eliquis) and rivaroxaban (Xarelto). They are considered by many doctors to have similar benefits and risks, but no one knows for sure. * The trial only enrolls patients with a diagnosis of atrial fibrillation ("A Fib") or atrial flutter. Most participants will be age 65 or older, and should already be taking apixaban or rivaroxaban. * The investigators will measure, in about 10,000 VA patients nationally, whether the rates of stroke, major bleeding, or death differ between these two drugs. * The trial will last about 7 years, but after the first prescription, all information will be collected from electronic medical records.
Interventions
- DRUG Apixaban
- DRUG Rivaroxaban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,000 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2033-10-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06953726
The ClinicalTrials.gov registry entry for NCT06953726 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 10,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Apixaban is the first listed.
NCT06953726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06953726 about?
NCT06953726 is a clinical study titled "Comparing the Safety and Efficacy of Apixaban and Rivaroxaban". * The trial will compare two anticoagulants ("blood thinners") that are currently used in the VA and are considered standard care to prevent strokes in patients with atrial fibrillation. The two most commonly-used anticoagulants will be compared: apixaban (Eliquis) and rivaroxaban (Xarelto). They ar...
What is the current status of trial NCT06953726?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 10,000 participants. The study started on 2026-06-01. Estimated completion is 2033-10-03.
What interventions are being tested in trial NCT06953726?
The interventions under investigation include: Apixaban (DRUG), Rivaroxaban (DRUG).
Who is sponsoring clinical trial NCT06953726?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.